Principal Investigator
Matthew Abramowitz
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20221263
Clinical Trial Summary
A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical
Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the
Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma
Phase
N/A
Funding Agency/Sponsor
Industrial
Disease
Cutaneous Malignancies
Contact Information
Phone Number
305-243-2647